STAT+: Why Stoke Therapeutics' Dravet syndrome drug is worth watching

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

Stoke Therapeutics is nearing FDA sign-off on a groundbreaking Phase 3 clinical trial designed to prove that its experimental drug for Dravet syndrome, a severe form of epilepsy, can both reduce the frequency of seizures, and for the first time, show an improvement in the cognition and behavior of patients. 

“To show improvement in cognition would set us apart from every other drug that is approved for Dravet. It’s never been done before,” Stoke CEO Ed Kaye told me. 

Continue to STAT+ to read the full story…